NICOLE RIVERA: Open Payments
NPI 1205002151 · WOODSTOCK, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,119 in 143 payments from 22 companies in 2025. Trend: 2023 $2,401 · 2024 $2,414 · 2025 $3,119
Food & beverage: $3,019Education: $100
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $496 |
| GENZYME CORPORATION | 14 | $348 |
| Janssen Biotech, Inc. | 15 | $325 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $301 |
| Madrigal Pharmaceuticals | 6 | $220 |
| Regeneron Healthcare Solutions, Inc. | 7 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $192 |
| Intercept Pharmaceuticals, Inc. | 13 | $179 |
| Lilly USA, LLC | 8 | $156 |
| Amgen Inc. | 1 | $126 |
Products named: DUPIXENT, TREMFYA, XIFAXAN, LINZESS, REZDIFFRA, OCALIVA, ENTYVIO, OMVOH.
Industry payments across GA — which companies pay providers there.
